



16th • 17th
February 2023

Innovation in Breast Cancer

iBC 2023

DIRECTOR

Miguel Martín
Hospital General Universitario Gregorio Marañón, Madrid

Innovation in Breast Cancer - iBC 2023

THURSDAY 16th February 2023

Introduction

Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

SESSION I: GENERAL TOPICS I

Chair: Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain

16:45-17:05 In vivo models in breast cancer research: where are we now

Karen Blyth, Beatson Institute for Cancer Research, Glasgow, UK

17:05-17:25 Overcoming endocrine resistance in breast cancer

TBC

17:25-17:45 Proton-therapy of Cancer: advantages over standard radiation and current indications

Felipe Calvo, Clinica Universitaria de Navarra, Madrid, Spain

17:45-18:15 Discussion

18:15-18:30 Break

SESSION II: EARLY BREAST CANCER

Chair: Luis Costa, Hospital de Santa María, Lisbon, Portugal

18:30-18:50 PARP-1 inhibitors: Any role as neoadjuvant therapy of early BRCA-1/2 associated breast cancer?

Steven Isakoff, Massachusetts General Hospital Cancer Center, Boston, USA

18:50-19:10 Advances in the adjuvant treatment of HR+/HER2- early breast cancer

Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

19:10-19:30 Chemo-immunotherapy for early triple negative breast cancer: which drugs?

Priyanka Sharma, University of Kansas Medical Center, Texas, USA

19:30-20:00 Discussion

FRIDAY 17th February 2023

SESSION III: GENERAL TOPICS II

Chair: Ander Urruticoechea, Onkologikoa, San Sebastián, Spain

16:00-16:20 ESMO guidelines for breast cancer: how are they made?

Curigliano Giuseppe, European Institute of Oncology, Milan, Italy

16:20-16:40 Adherence to oral breast cancer therapies

Iván Bustillos, Clínica Portoazul Auna, Barranquilla, Colombia

16:40-17:00 De-escalation of antineoplastic therapies: Principles and considerations

Henk van Halteren, Adrz-Admiraal de Ruijter, Medical Cener, Goes, Netherlands

17:00-17:30 Discussion

17:30-17:45 Break

SESSION IV: TREATMENT OF METASTATIC BREAST CANCER

Chair: José Enrique Alés, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain

17:45-18:05 What have we seen from oral SERDs and what could they mean for our patients in future?

Aditya Bardia, Massachusetts General Hospital Cancer Center, Boston, USA

18:05-18:25 Safety management of Antibody-Drug-Conjugates

Maryam Lustberg, Yale University School of Medicine, New Heaven, USA

18:25-18:45 Managing brain metastases for HER2+ breast cancer

Diana Lüftner, Charité Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany

18:45-19:15 Discussion

19:15 Closing remarks

Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Innovation in Breast Cancer – iBC 2022

Organized by



With the scientific endorsement of



Accreditation

Continuing Education Credits requested
to the Spanish National Health System

Symposium secretariat

doctaforum
MEDICAL MARKETING SPECIALISTS | Tel.: (+34) 91 372 02 03
e-mail: ibc@doctaforum.com
www.innovationinbreastcancer